Instrument Inactif

Communiqués Global Blood Therapeutics, Inc.

Actions

GBT

US37890U1088

Recherche biotechnologique et médicale

Communiqués

05/10/22	GLOBAL BLOOD THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Regi (form 8-K)	AQ
30/09/22	GLOBAL BLOOD THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	AQ
23/09/22	GLOBAL BLOOD THERAPEUTICS, INC. : Other Events (form 8-K)	AQ
16/09/22	GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022	AQ
08/09/22	GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference	AQ
31/08/22	GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT	BU
09/08/22	Global Blood: Q2 Earnings Snapshot	AQ
09/08/22	GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT	BU
08/08/22	Global Blood Therapeutics : Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology - Form 8-K	PU
08/08/22	GLOBAL BLOOD THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
08/08/22	GLOBAL BLOOD THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/08/22	GBT Announces New Employment Inducement Grants	AQ
03/08/22	GBT Announces Participation at the Wedbush PacGrow Healthcare Conference	AQ
01/08/22	GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022	AQ
29/07/22	GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022	AQ
27/07/22	Global Blood Therapeutics, Inc. - MHRA Grants Marketing Authorization for GBT's Oxbryta (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease	AQ
26/07/22	Global Blood Therapeutics : MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older - Form 8-K	PU
26/07/22	GLOBAL BLOOD THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
26/07/22	MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older	GL
26/07/22	MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older	AQ
14/07/22	Global Blood Therapeutics : GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil - Form 8-K	PU
14/07/22	GLOBAL BLOOD THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
14/07/22	GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil	AQ
14/07/22	Global Blood Therapeutics, Inc. - The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations	AQ
13/07/22	The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations	AQ